HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes

Table 1 Summary of Gag amino acid substitutions in HIV-1 non-B subtypes observed during PI-based treatment

Gag amino acid substitutions in non-B subtypes*	Number of patients infected by non-B subtypes	Reference
A431V	A or F^# (n = 4)	[8]
K436R, N451S	C (n = 1)	[8]
L363F, A364G, A374T, I376V, M378V, R380K, K436E, G443R	G (n = 2), 01_AE (n = 1), 02_AG (n = 4)	[9]
V128A/T/I, Q130R, Y132F, V135M, V362I, A373T, A374T, A375T, I376A/V/M, K380R, S381G, N382K, E428D/Q, Q430R/G/V/I, A431V, K436R, L449I, N451S, R452K, P453I	G (n = 21)	[10]
N375S, G381R	A1 (n = 2)	[2]
G381S, G446E	02_AG (n = 1)	[2]
V135I, I376V, L486F	01_AE (n = 1)	[2]
P453L/T/I	F^# (n = 61)	[11]
M138L, F363L, L363W, A374T, V374A, R387K, N389T, K411Q, K415R, G420A, P422Q, T427P, P445L, S451G, R452G, P453L, P453Ins, I469T, P472S, P474L, E477Q	A1 (n = 1), C (n = 6), D (n = 1), F1 (n = 1), J (n = 1), 01_AE (n = 1), 02_AG (n = 1)	Our study

*Non-B Gag substitutions reported during PI-based treatment. The substitutions are summarized based on the original publications, and for the substitutions in our study, it is given relative to the baseline sequences sampled from individual patients (see Figure 1). The substitutions also identified in subtype B are indicated in bold. Additional file 1: Table S1 summarizes the information of Gag substitutions in HIV-1 subtype B.
^#Information of HIV-1 subtype or sub-subtype was ambiguous or not available.

ISSN: 1742-4690